Clinical trials: Aggressive Behaviour
Breast Cancer
Reirradiation With Concurrent Paclitaxel for Breast Cancer
The purpose of this trial in addition to a dose finding study for concurrent Paclitaxel, will be to establish a treatment algorithm for chest wall reirradiation.
- Trial name
- NCT02058667
- Testing
- Paclitaxel+Initial Radiation+Boost
- Where
- United States
- Sponsor
- University of Kentucky
Skin Cancer
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
The goal of this clinical research study is to learn if Tarceva ® (erlotinib) when taken before and after radiation and/or surgery can help to control aggressive cutaneous squamous cell carcinoma.
- Trial name
- NCT01059305
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Aggression
Effectiveness of Treatment for Relational Aggression in Urban African American Girls
This study will evaluate the effectiveness of a school-based social cognitive group treatment in reducing aggression (bullying) among relationally aggressive urban African American girls.
- Trial name
- NCT00510094
- Testing
- Friend to Friend program, Psychoeducational attention control intervention
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Children's Hospital of Philadelphia
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT03483103
- Testing
- lisocabtagene maraleucel
- Where
- 59 sites in United States
- Volunteers
- 74 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Schizophrenia
Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward
The purpose of this study is to compare the efficacy and tolerability of zotepine versus Risperidone in aggressive schizophrenic patients.
- Trial name
- NCT00418873
- Testing
- Zotepine, Risperidone
- Where
- 4 sites in Taiwan
- Volunteers
- 39 people
- Sponsor
- Astellas Pharma Inc
Traumatic Brain Injury
Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression
The purpose of this study is to determine if carbamazepine reduces irritability and aggression among individuals with traumatic brain injury
- Trial name
- NCT00621751
- Testing
- Carbamazepine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Desmoid Tumors, Aggressive Fibromatosis
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Background: Desmoid tumors (also known as aggressive fibromatosis), are rare, locally invasive, slow-growing soft-tissue tumors.
- Trial name
- NCT01981551
- Testing
- PF-03084014
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
- Trial name
- NCT00807495
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
This phase II trial studies the side effects and how well high-dose yttrium-90 (Y-90)-ibritumomab tiuxetan (anti-cluster of differentiation [CD]20) followed by fludarabine phosphate, low-dose total body irradiation (TBI), and…
- Conditions
- Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma
- Trial name
- NCT01434472
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, B-Cell
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
This study seeks to determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-Cell Non-Hodgkin's…
- Trial name
- NCT00515138
- Testing
- Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Genetic Predisposition
Prostate Tissue BioBank
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13.
- Trial name
- PTBB (NCT06659614)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-small Cell Lung Cancer, Spread Through Air Space
Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer
The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting aggressive histological pattern in resected non-small cell lung cancer based on a multicenter prospective cohort.
- Conditions
- Non-small Cell Lung Cancer, Spread Through Air Space, Visceral Pleural Invasion, Lymphovascular Invasion
- Trial name
- NCT05925738
- Testing
- PET/CT-based Deep Learning Signature
- Where
- 3 sites in China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT03210662
- Testing
- External Beam Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Aggressive Lymphoma, Diffuse Large B-cell Lymphoma
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.
- Conditions
- Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- RGemOx (NCT01562977)
- Testing
- Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
- Where
- 28 sites in Spain
- Volunteers
- 82 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm, Mast Cell Leukemia
- Trial name
- NCT04695431
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 317 people
- Sponsor
- Blueprint Medicines Corporation
Problem Drinking, Aggression
Feasibility and Acceptability of Mindfulness-based Resilience Training for Rural Law Enforcement Officers
Rural law enforcement officers (LEOs) are exposed to unique and significant stressors, yet have access to fewer resources, compared to urban counterparts, to mitigate harmful effects of stress.
- Conditions
- Problem Drinking, Aggression, Stress, Psychological
- Trial name
- NCT05629637
- Testing
- Mindfulness-Based Resilience Training (MBRT)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pacific University
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Aggression
An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years
In this study, the investigators propose to examine whether the combination of a universal, elementary school-based preventive intervention with an indicated preventive and treatment intervention would yield greater impact on…
- Trial name
- P2P+IY (NCT03132805)
- Testing
- PATHS to PAX, PATHS to PAX and the Incredible Years
- Where
- United States
- Volunteers
- 5,233 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Lymphoma
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00363090
- Testing
- alemtuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre